Browsing by Author "Hassan S.S."

Filter results by typing the first few letters
Now showing 1 - 2 of 2
  • Thumbnail Image
    Item
    Dysregulation of miR-125b predicts poor response to therapy in pediatric acute lymphoblastic leukemia
    (Wiley-Liss Inc., 2019) El-Khazragy N.; Elshimy A.A.; Hassan S.S.; Matbouly S.; Safwat G.; Zannoun M.; Riad R.A.; Department of Clinical Pathology and Hematology; Faculty of Medicine; Ain Shams Medical Research Institute (MASRI); Ain Shams University; Cairo; Egypt; Former Department of Biomedical Research; Armed Forces College of Medicine (AFCM); Cairo; Egypt; Department of Medical Microbiology and Immunology; Faculty of Medicine; Cairo University; New Giza University; Cairo; Egypt; Department of Clinical Pathology; National Cancer Institute; Cairo University; Cairo; Egypt; Department of Pediatrics; Faculty of Medicine; Ain Shams University; Cairo; Egypt; Department of Cancer Biology; Faculty of Biotechnology; October University for Modern Sciences and Art (MSA) University; Cairo; Egypt; Department of Pediatrics; Faculty of Medicine; Al Azhar University; Cairo; Egypt; Department of Biotechnology and Molecular Biology; Global Research Lab; Cairo; Egypt
    Background: Acute lymphoblastic leukemia (ALL) is the most well-known sort of leukemia in children. In spite of favorable survival rates, some patients relapse and achieve a poor outcome. Methods: We analyzed miR-125b and Bcl-2 expressions in pediatric patients with ALL and evaluated their clinical utility as molecular markers for the prediction of disease outcomes. Results: Downregulation of miR-125b and increased Bcl-2 expression levels in pediatric patients with ALL were associated with poor prognosis at diagnosis. At day 28 of induction, miR-125b was significantly increased, whereas Bcl-2 was downregulated. Loss of miR-125b during diagnosis and its elevation after therapy are strongly correlated with short leukemia-free survival and worse survival. Moreover, the combination of miR-125b with Bcl-2 markers can clearly enhance the prediction of the disease outcome. Finally, a univariate analysis highlighted the independent prognostic value of miR-125 in a pediatric patient with ALL. Conclusions: miR-125b and Bcl-2 together are potent predictors for the prognosis and, therefore, can be used as therapeutic targets in childhood ALL. � 2018 Wiley Periodicals, Inc.
  • Thumbnail Image
    Item
    In vitro knock-out of miR-155 suppresses leukemic and HCV virus loads in pediatric HCV-4 associated acute lymphoid leukemia: A promising target therapy
    (Wiley-Liss Inc., 2019) Hassan S.S.; El-Khazragy N.; Elshimy A.A.; Aboelhussein M.M.; Saleh S.A.; Fadel S.; Atia H.A.; Matbouly S.; Tamer N.; Clinical Pathology Department; National Cancer Institute; Cairo University; Cairo; Egypt; Clinical Pathology/Hematology and Biomedical Research Departments; Faculty of Medicine; Ain Shams University; Cairo; Egypt; Biomedical Research Department; Global Research Labs; Cairo; Egypt; Medical Microbiology and Immunology Department; Faculty of Medicine; Cairo University and New Giza University; Cairo; Egypt; Medical Biochemistry and Molecular Biology Department; Faculty of Medicine; Ain- Shams University; Cairo; Egypt; Internal Medicine Department; Faculty of Medicine; Ain- Shams University; Cairo; Egypt; Pediatric Oncology Department; National Cancer Institute; Cairo University; Giza; Egypt; Clinical Pathology Department; Faculty of Medicine; New Giza University; Giza; Egypt; Department of Pediatrics; Faculty of Medicine; Ain Shams University; Cairo; Egypt; Faculty of Biotechnology; October University for Modern Sciences and Arts (MSA); Giza; Egypt
    Hepatitis C virus (HCV) infection is a major public health problem, having a high prevalence in Egypt. Leukemia and lymphoma have been associated with HCV infection. MicroRNA-155 (miR-155) has been reported to play a regulatory role in cancer, inflammation, and immune response to infection. The expression level of miR-155 in HCV viremic patients is controversial; although high miR-155 levels were demonstrated in HCV genotypes 1,2, and 3, low levels of miR-155 were detected in Egyptian patients with HCV genotype 4. Several studies have investigated the correlation between the levels of miRNA-155 and the replication of HCV, others have evaluated miRNA-155 as a prognostic biomarker in different types of cancer. No studies have investigated the impact of miRNA-155 knockdown on HCV pediatric patients associated with childhood acute lymphoblastic leukemia (ALL). We knocked-out the miR_155a in cultured polymorphonuclear cells (PBMCs) obtained from 60 children with ALL; 30 were associated with HCV-4 infection and 30 were HCV negative. The miR_155a, HCV viral load, and cell proliferation werre assessed in treated and untreated cells using TaqMan assay quantitative polymerase chain reaction. We found that miRNA-155 was significantly upregulated by seven folds in the HCV-4 associated ALL group; while being linked to high HCV viral load and leukemic burden, miR_155a knock-out can improve the disease outcome. We conclude that miR-155 is a critical miRNA that is considered a therapeutic target in pediatric HCV leukemic patients. 2019 Wiley Periodicals, Inc.